Search

Your search keyword '"Li, Wenyu"' showing total 35 results
Start Over Author "Li, Wenyu" Journal blood
35 results on '"Li, Wenyu"'

3. Efficacy and Safety of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma in China

Author

Song, Yuqin, primary, Ying, Zhitao, additional, Yang, Haiyan, additional, Guo, Ye, additional, Li, Wenyu, additional, Zou, Dehui, additional, Wu, Jianqiu, additional, Tian, Alex, additional, Huang, Tony, additional, Zhou, Zisong, additional, Ma, Meilin, additional, Yang, Su, additional, Qin, Yun, additional, and Zhu, Jun, additional

Published
2022
Full Text
View/download PDF

4. Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China

Author

Lin, Zhijuan, primary, Zha, Jie, additional, Yi, Shuhua, additional, Li, Zhifeng, additional, Ping, Lingyan, additional, He, Xiaohua, additional, Fan, Liyuan, additional, Yu, Haifeng, additional, Zheng, Zhong, additional, Xu, Wei, additional, Chen, Feili, additional, Xie, Ying, additional, Chen, Bi-yun, additional, Zhang, Huilai, additional, Wang, Li, additional, Ding, Kaiyang, additional, Li, Wenyu, additional, Yang, Haiyan, additional, Zhao, Weili, additional, Qiu, Lugui, additional, LI, Zhiming, additional, Song, Yuqin, additional, and Xu, Bing, additional

Published
2022
Full Text
View/download PDF

6. Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)

Author

Shi, Yuankai, primary, Song, Yongping, additional, Zhang, Mingzhi, additional, Jing, Hongmei, additional, Wang, Zhen, additional, Li, Zhiming, additional, Qi, Junyuan, additional, Li, Fei, additional, Li, Wenyu, additional, Yang, Jianliang, additional, Gao, Siman, additional, Ma, Huizi, additional, He, Heming, additional, Lu, Qiying, additional, and Tian, Wenzhi, additional

Published
2022
Full Text
View/download PDF

7. Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China

Author

Ma, Jun, primary, Zhiming, Li, additional, Xu, Wei, additional, Liu, Yao, additional, Zhao, Weili, additional, Yao, Zhihua, additional, Ding, Kaiyang, additional, Wu, Yudan, additional, Liu, Hong, additional, Li, Wenyu, additional, Jiang, Yirong, additional, Lin, Li'e, additional, Peng, Zhigang, additional, and Zhai, Zhimin, additional

Published
2022
Full Text
View/download PDF

8. A Preliminary Analysis of Chidamide Combined with R-GemOx (rituximab, gemcitabine and oxaliplatin) As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Study

Author

Cai, Qingqing, primary, Xia, Yi, additional, Zhou, Hui, additional, Li, Wenyu, additional, Li, Zhiming, additional, Ye, Xu, additional, Wu, Yudan, additional, Tan, Huo, additional, Zheng, Runhui, additional, Wu, Bingyi, additional, Yang, Hui, additional, Lu, Yuhong, additional, Liang, Yang, additional, Su, Ning, additional, Zou, Qihua, additional, and Liu, Panpan, additional

Published
2022
Full Text
View/download PDF

10. Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China

Author

Song, Yuqin, primary, Ying, Zhitao, additional, Yang, Haiyan, additional, Guo, Ye, additional, Li, Wenyu, additional, Zou, Dehui, additional, Zhou, Daobin, additional, Wang, Zhao, additional, Zhang, Mingzhi, additional, Wu, Jianqiu, additional, Liu, Hui, additional, Zhang, Pian, additional, Yang, Su, additional, Zhou, Zisong, additional, Zheng, Hongxia, additional, and Zhu, Jun, additional

Published
2021
Full Text
View/download PDF

13. Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Author

Song, Yuqin, Malpica, Luis, Cai, Qingqing, Zhao, Weili, Zhou, Keshu, Wu, Jianqiu, Zhang, Huilai, Ding, Kaiyang, Liu, Yao, Li, Zengjun, Mehta-Shah, Neha, Zhang, Liling, Zheng, Meifang, Jin, Jie, Yang, Haiyan, Shuang, Yuerong, Yoon, Dok Hyun, Gao, Sujun, Li, Wenyu, Zhai, Zhimin, Zou, Liqun, Xi, Yaming, Koh, Youngil, Li, Fei, Prince, Miles, Zhou, Hui, Lin, Lie, Liu, Hui, Yang, Zhenfan, Kim, Won Seog, and Zhu, Jun

Published
2023
Full Text
View/download PDF

16. Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Author

Lin, Ningjing, Sun, Xiuhua, Zhou, Hui, Zou, Liqun, Zhou, Keshu, Liu, Lihong, Yang, Haiyan, HU, Kai, Cai, Qingqing, Liu, Yao, Jin, Jie, Zhang, Liling, Li, Wenyu, Guo, Ye, Yang, Wei, Luo, Feng, Li, Yanyan, Zhang, Mengqi, Lu, Feinan, Song, Yuqin, and Zhu, Jun

Published
2023
Full Text
View/download PDF

20. Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study

Author

Cai, Qingqing, primary, Zhou, Hui, additional, Li, Zhiming, additional, Li, Wenyu, additional, Wu, Yudan, additional, Wu, Bingyi, additional, Yang, Hui, additional, Liang, Stephen Yang, additional, Su, Ning, additional, Liu, Panpan, additional, Zhang, Xuanye, additional, Xia, Yi, additional, and Ma, Shuyun, additional

Published
2020
Full Text
View/download PDF

22. Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China

Author

Zhu, Jun, primary, Ying, Zhitao, additional, Song, Yuqin, additional, Yang, Haiyan, additional, Guo, Ye, additional, Li, Wenyu, additional, Zou, Dehui, additional, Zhou, Daobin, additional, Wang, Zhao, additional, Zhang, Mingzhi, additional, Wu, Jianqiu, additional, Liu, Hui, additional, Zhang, Pian, additional, Yang, Su, additional, Zhou, Zisong, additional, and Zheng, Hongxia, additional

Published
2020
Full Text
View/download PDF

23. Efficacy and Safety Analysis of Ibrutinib-Containing Therapy for Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from a Real-World Study in China

Author

Cai, Qingqing, primary, Huang, Huiqiang, additional, Zhang, Yuchen, additional, Liu, Panpan, additional, Jing, Hongmei, additional, Yang, Ping, additional, Lin, Tongyu, additional, Xia, Zhongjun, additional, Li, Zhiming, additional, Li, Wenyu, additional, Zhong, Liye, additional, Ye, Xu, additional, Jin, Xueli, additional, Zhang, Liling, additional, Zhang, Huilai, additional, Sun, Xiuhua, additional, Tian, Yuyang, additional, Ma, Shuyun, additional, Su, Ning, additional, and Cai, Jun, additional

Published
2020
Full Text
View/download PDF

24. Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Author

Gao, Yan, primary, Huang, Huiqiang, additional, Wang, Xiaoxiao, additional, Bai, Bing, additional, Zhang, Liling, additional, Xiao, Yin, additional, Liu, Xinxiu, additional, Li, Wenyu, additional, Xu, Wei, additional, Feng, Ru, additional, Chen, Yu, additional, Wu, Huijing, additional, Li, Jibin, additional, and Wu, Xue, additional

Published
2020
Full Text
View/download PDF

25. Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

Author

Huang, Hui-qiang, primary, Yan, Gao, additional, Su, Hang, additional, Huang, Yunhong, additional, Gao, Yuhuan, additional, Xiaoxiao, Wang, additional, Bing, Bai, additional, Zhang, Yujing, additional, Su, Liping, additional, Chu, Xiaoxia, additional, Li, Wenyu, additional, Zhang, Junyi, additional, Zhang, Qiaohua, additional, Zhang, Liansheng, additional, Hu, Xiaohua, additional, Zou, Liqun, additional, Li, Zhiming, additional, and Jiang, Wenqi, additional

Published
2019
Full Text
View/download PDF

26. An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Author

Tam, Constantine S., primary, Cull, Gavin, additional, Opat, Stephen, additional, Gregory, Gareth P, additional, Liu, Aichun, additional, Johnston, Anna M., additional, Zhao, Weili, additional, Roncolato, Fernando, additional, Handunnetti, Sasanka M., additional, Prince, H. Miles, additional, Yannakou, Costas K., additional, Li, Wenyu, additional, Shih, Ted, additional, Zhang, Xiaoping, additional, Wu, Ken, additional, Liu, Yuan, additional, Huang, Jane, additional, and Trotman, Judith, additional

Published
2019
Full Text
View/download PDF

30. Pegaspargase Plus Gemcitabine, Oxaliplatin(P-Gemox) and Thalidomide Versus Aspermetdex Regimen for the Patients with Early or Advanced/Relapsed Extranodal Natural Killer/T Cell Lymphoma: Interim Analysis of a Prospective,Multicenter, Randomized, Phase III Non-Inferiority Clinical Trial

Author

Gao, Yan, primary, Huang, Huiqiang, additional, Zhang, Yujing, additional, Su, Hang, additional, Wang, Xiaoxiao, additional, Bai, Bing, additional, Huang, Yunhong, additional, Gao, Yuhuan, additional, Su, Liping, additional, Chu, Xiaoxia, additional, Li, Wenyu, additional, Zhang, Junyi, additional, Zhang, Qiaohua, additional, Zhang, Liansheng, additional, Hu, Xiaohua, additional, Zou, Liqun, additional, Li, Zhiming, additional, and Jiang, Wenqi, additional

Published
2016
Full Text
View/download PDF

31. Ferroptosis Inhibition Generates TCF-1 +CAR-T Cells with Enhanced Persistence and Cytotoxicity

Author

Harada, Shinpei, Hashimoto, Daigo, Saito, Yumika, Miyajima, Toru, Li, Wenyu, Senjo, Hajime, Zhang, Zixuan, Kikuchi, Ryo, Chiba, Masahiro, Ohigashi, Hiroyuki, Ara, Takahide, Nakagawa, Masao, and Teshima, Takanori

Abstract

[Introduction]Long-term in vivopersistence of chimeric antigen receptor (CAR) T-cells is associated with sustained response after CAR-T cell therapy against hematological malignancies. Ferroptosis is a novel form of programmed cell death that refers to iron-dependent regulated cell death resulting from lipid peroxidation and consequent cytomembrane rupture. The iron, lipid, amino acid, and glutathione metabolisms strictly govern the beginning and execution of ferroptosis. Recent studies demonstrated that ferroptosis limited longevity of virus-specific memory T cells (Wang Y: Nat Immunol 2022). However, the role of ferroptosis in CAR-T cells remains to be clarified. We herein explored the role of ferroptosis in CAR-T cells both in vitroand in vivo. [Methods]For CAR-T cell generation, purified T cells from naïve mice were stimulated with anti-CD3/CD28 antibodies for 48 hrs and then incubated with retroviral vector encoding anti-CD19 CAR (1D3-28Z.1-3; Addgene) for another 48 hrs, in the presence or absence of 32 µM of ferrostatin-1 (Fer-1), an inhibitor of the iron-dependent production of lipid hydroperoxide, or 10 µM of deferoxamine (DFO), an iron chelator. Flow cytometric analyses of phenotype of CAR-T cells, accumulation of reactive oxygen species (ROS), lipid peroxidation, and cytokine production were performed 96 hrs after T-cell stimulation. ROS were quantified using CellROX Green dye, and lipid peroxidation was evaluated using Lipid Peroxidation Assay Kit (abcam). [Results]First, we tested whether CAR-T manufacturing process could induce ferroptosis. We found a substantial accumulation of ROS in CAR-T cells compared to their pre-culture levels, along with a significant increase in lipid peroxidation, indicating that manufacturing process induces ferroptosis of CAR-T cells. Next, we tested whether ferroptosis inhibition by the lipid peroxidation inhibitor Fer-1, could impact the quality of CAR-T cells. When added to the culture, Fer-1 significantly reduced lipid peroxidation in CAR-T cells and significantly increased the proportion of CAR-T cells with a progenitor phenotype, TCF-1 +Tim-3 -, which is known to be associated with longevity of CAR-T cells. Importantly, ferroptosis inhibition significantly enhanced proliferative capacity and cytotoxicity against syngeneic A20 B-cell leukemia in vitro. Next, we tested whether ferroptosis inhibition by the iron chelator DFO could improve CAR-T cell functions. Similar to the effects of Fer-1, DFO mitigated lipid peroxidation of CAR-T cells in association with increased TCF-1 +Tim-3 -population, while it did not affect ROS accumulation. DFO-treated CAR-T cells demonstrated enhanced cytotoxicity against A20 cells compared with control CAR-T cells, confirming that ferroptosis inhibition improves anti-tumor effects of CAR-T cells. Finally, we examined whether ferroptosis inhibition could enhance antitumor effects of CAR-T cells in vivo. Naïve BALB/c mice were intravenously (i.v.) injected with 1.0 x 10 6luciferase-expressing A20 cells on day 0, followed by i.v. injection of 1.0 x 10 5Fer-1- or DFO-treated CAR-T cells or control CAR-T cells 7 days later. In mice injected with Fer-1-treated CAR-T cells, the numbers of CAR-T cells in peripheral blood on day 16 was significantly higher than those in mice injected with control CAR-T cells, suggesting that ferroptosis inhibition improved the persistence of CAR-T cells in vivo( Fig. 1). In vivobioluminescence imaging showed that both Fer-1-treated and DFO-treated CAR-T cells demonstrated significantly improved anti-tumor effects compared to control CAR-T cells ( Fig. 2). [Conclusions]We for the first time showed that ferroptosis limits the persistence and anti-tumor effects of CAR-T cells, while ferroptosis inhibition induces TCF-1 +Tim-3 -CAR-T cells and improves the therapeutic effect of CAR-T cell therapy.

Published
2023
Full Text
View/download PDF

34. Next Generation Sequencing Highlights the Role of Cell Cycle and Apoptosis Dysregulation and Hepatitis B Infection in Refractory Diffuse Large B Cell Lymphoma

Author

Li, Wenyu, Jiang, Xinmiao, Guo, Hanguo, Wei, Xiaojuan, Chen, Feili, Liu, Sichu, Huang, Ling, and Liang, Zhanli

Abstract

About 10-15% DLBCL are primary refractory, the underlying biology aggressiveness contributed to refractoriness remain to be defined. To date, whole-exome (WES) or whole-genome sequences (WGS) obtained from primary or refractory/relapse DLBCL tumors have been published, while the biology study conduct on patients of mixed prognosis failed to characterizing the 10-15% primary refractory cases, and WES or WGS are not applicable in clinical routine practice. To address this issue, we performed target next generation sequencing in 11 primary refractory DLBCL cases. Through pathway enrichment analysis, as expected, the cell cycle/apoptosis and P53 signaling (FDR 10-11~10-9), NF-kB (FDR ~10-9), BCR signaling(FDR ~10-9), PI3K/Akt (FDR ~10-8), MAPK(FDR ~10-10), Wnt (FDR ~10-12), Jak/STAT (FDR ~10-14) signaling were significant mutated. Furthermore, some pathogen infection pathways were also significantly affected, which was not identified as significantly mutated in previous DLBCL WGS studies, including hepatitis B virus infection(HBV) signaling pathway involving BCL-2, MYC, MYD88, CREBBP, FAS, STAT3, TP53, and 4 of the 11 (36.4%) patients were HBsAg-positive. Overall, somatic mutations or copy number aberrations of CD79B (5/11, 45.5%), TP53(4/11, 36.3%), PIM1 (4/11, 36.3%) , MYD88 (3/11, 27.2%), KMT2D (3/11, 27.2%), CREBBP(3/11, 27.2%) and IRF4 (3/11, 27.2%) were the most prevalent aberrations. We separately compared the prevalence of target gene variants in our refractory (ref)-DLBCLs to published cohorts of responsive or de novo or relapse(rel) or relapse/refractory(r/r)-DLBCLs, the profile and frequency was highly concordant to those of relapse ones, while CD79B and cell cycle regulation or apoptosis related genes were more prevalent affected in our refractory cohort than those of responsive or de novo ones(table 2).

Published
2017
Full Text
View/download PDF

35. Neutrophils Extracellular Traps Induced By Lymphoma-Derived IL-8 Could Promote Diffuse Large B Cell Lymphoma Progression

Author

Nie, Man, Yang, Linbing, Bi, Xiwen, Wang, Yu, Sun, Peng, Yang, Hang, Liu, Panpan, Li, Zhiming, Xia, Yi, Jiang, Wenqi, and Li, Wenyu

Abstract

Background: Neutrophils extracellular traps (NETs) are extracellular strands of decondensed DNA in complex with citrullinated histones (H3cit) and granule proteins including myeloperoxidase (MPO) (Sørensen O E, et al. 2016). Although this structure was initially described as an antimicrobial defense mechanism (Brinkmann V, et al. 2007), recent evidence has linked NETs to tumor metastases, and a previous study has demonstrated that the interaction of NETs and CD5+ B cells favored the transition from autoimmunity to lymphoma (Sangaletti S, et al. 2014). But it remains unclear whether NETs promote diffuse large B cell lymphoma (DLBCL) progression and can be a therapeutic candidate. Thus, our objectives were to detect NETs in the DLBCL samples, define the role of NETs in progression of DLBCL and reveal the underlying mechanism.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results